Supplementary Figure 1

Jul 28, 2014

10 likes | 163 Vues

Supplementary Figure 1. Percentage of short telomeres. p =0.278.

Share Presentation

Embed Code

Link

percentageof
median percentage
molecular breast cancer subtypes
luminal b
hereditary tumors
her2-positive subtypes

ataret

Télécharger la présentation

Supplementary Figure 1

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

Supplementary Figure 1 Percentageof short telomeres p=0.278 Supplementary Figure 1. Differences in the percentage of short telomeres among the hereditary tumors of the established molecular breast cancer subtypes. Box-plots representing the distribution of the percentage of ST among subtypes, B: Basal, LA: Luminal A, LB: Luminal B and HER2: HER2-positive subtypes. The median percentage of each group is indicated by a black bar.

Supplementary figure 1

Supplementary figure 1. Supplementary figure 2 . sNF96.2. ST88-14. T265-2C. NF90.8. Supplementary figure 3. NF90.8. sNF96.2. T265-2C. ST88-14. Supplementary figure 4. A. B. NF90.8. siRNA mTOR#13. siRNA mTOR#19. siRNA GFP. mTOR. GAPDH. ST88-14. siRNA mTOR#13.

209 views • 12 slides

Supplementary Figure 1

Supplementary Figure 1. MW/1000. pH. SJIA. POLY. Others. F. FI. F. KD. Q. Q. C3. AGP1. ACT. SAP. SAA. S100A8. S100A9. HP. CRP. C9. C4. APO-IV. APO-L1. AMBP. KLKB1. VDB. CFH. ATIII. A2M. ATIII. APO-E. APO-D. FGG FGB. TTR. GSN. APOA1. Figure 1. 12. 10. 8.

181 views • 7 slides

Supplementary Figure 1

Supplementary Figure 1. A. B. C. Supplementary Figure 2. Supplementary Figure 3. A. PHTX-14B Day 10. B. MDA-MB-231 Day 10. Supplementary Figure 4. Vehicle. MLN8237 20mg/kg QDx3/wk. Treatment Period. 2500. 2000. 1500. Average Tumor Volume (mm^3). 1000. 500. 0. 0. 10. 20.

248 views • 5 slides

Supplementary Figure 1

Supplementary Figure 1. 3. 2,5. 2. 1,5. 1. 0,5. 0. 6. 5. 4. 3. 2. 1. 0. A. WT with FSK+Gen. WT with FSK. lF508del with FSK+Gen. lF508del with FSK. ns. ns. ns. ns. Bicarbonate secretion ( normalized to the rate in FSK-treated F508del as 1). 10 min post peak response.

107 views • 2 slides

Supplementary Figure 1

Supplementary Figure 1. a. b. c. a continuous schedule for 35 consecutive days. an intermittent schedule. DNA vaccination (50 ug/mouse). DNA vaccination (50 ug/mouse). A20 Lymphoma. A20 Lymphoma. Day. Day. 1. 35. 0. 14. 28. 0. 14. 28. 42. 21. 18. 35. 42. 32. 7. 4.

95 views • 3 slides

Supplementary Figure 1

a. *. *. ns. 3. 2. RANK Arbitrary Score. 1. 0. b. RANK. 1 2 3 4 5 6 7 8 9 10 11. Metastasis lymph node. Primary tumor. Normal breast. Supplementary Figure 1. Prolactin. RANKL. RANKL. pERK1/2. pERK1/2. pAKT. ERK1/2. AKT. b -Actin. pSTAT5. STAT5.

163 views • 7 slides

Supplementary Figure 1

Supplementary Figure 1. HM466934. I. II. pre-A. A. B. C. D/E. Supplementary Figure 2. V. IV. HM466934. HM466934. VI. HM466934. Supplementary Figure 3. HM466935. CDUV. Supplementary Figure 4. 34. MRMBV. MRCV. TUAV. ORXV. ALEV.

165 views • 4 slides

Supplementary Figure 1

IgVH unmutated. IgVH mutated. Low-risk. Intermediate-risk. High-risk. P14 cluster. N6 cluster. ZAP-70. CD38. IgVH status. Supplementary Figure 1.

81 views • 1 slides

Supplementary Figure 1

Supplementary Figure 1. CEPH: CYP2C8 (40kb, chr10:96782845..96822844). MAF=0.05. B. Hap-B. Hap-E. Hap-F. Haplotypes above 2%. Hap-A. Hap-D. Hap-C1+C2. Hap-C3. 3´UTR. CYP2C8. Pr. A. JPT+HCB: Asian. YRI: African. Supplementary Figure 2. A. B. C. A. B. C. Hap D (*3). Hap B.

196 views • 3 slides

Supplementary Figure 1

A. B. D. C. E. CD20. CagA. Merge. DAPI. Supplementary Figure 1.

168 views • 2 slides

Supplementary Figure 1

Nephrin. Nephrin. Nephrin. Nephrin. Nephrin. Synaptopodin. Synaptopodin. Synaptopodin. Synaptopodin. Synaptopodin. A. Merge. Merge. Merge. Merge. Merge. B. Podocin. Podocin. Podocin. Podocin. Podocin. Day 28. Control. Day 3. Day 15. Day 7. ADRN 11 mg/kg. Cont. Day3.

65 views • 1 slides

Supplementary Figure 1

Supplementary Figure 1. A. MIG (pMSCV-ires-GFP). I. GFP. LTR. LTR. MIG-PL2 (pMSCV-PLAGL2-ires-GFP). PL2. GFP. LTR. LTR. I. B. CBFb-MYH11 + HPs. GFP sort. Gene expression profile. Genes commonly deregulated in PL2+ cells. MIG-PL2 transduction. MIG transduction. GFP sort.

123 views • 1 slides

Supplementary Figure 1

Supplementary Figure 1. A. B. C.

71 views • 1 slides

Supplementary Figure 1.

MgrA. MepR. Supplementary Figure 1.

63 views • 1 slides

Supplementary Figure 1

90. 85. 80. 75. 70. 65. 40. 44. 48. 52. 56. 90. 80. 70. 60. 50. 38. 40. 42. 44. 46. 48. 50. 52. 90. 80. 70. 60. 50. 40. 30. 25. 30. 35. 40. 45. 50. 55. Normal. r = 0.043. p = 0.678. Methylation Level of LINE1 (%). Background. r = 0.063. p = 0.559.

87 views • 3 slides

Supplementary Figure 1

Supplementary Figure 1. Nominal p-value =0.0 FDR q-value= 0.19. Nominal p-value =0.004 FDR q-value= 0.30. Nominal p-value =0.013 FDR q-value= 0.19. Nominal p-value =0.033 FDR q-value= 0.18. Nominal p-value = 0.007 FDR q-value= 0.18. Nominal p-value =0.075 FDR q-value= 0.19.

114 views • 5 slides

Supplementary Figure 1

Supplementary Figure 1. Venkatachalam et al. 2013. ab. a. ab. abc. c. 24 48 72 96 120. Hours after FB17 treatment. Supplementary Figure 2. Venkatachalam et al. 2013. At1g11610. At3g28360. At1g21240. At3g14460. At3g20190. UBQ1.

134 views • 4 slides

Supplementary Figure 1

Supplementary Figure 1. Expansion of MSCs in 20% oxygen vs 5% oxygen. Supplementary Figure 2. Expansion of Kaneka-filtered cells in Flasks (P4) and the Quantum (P2). Supplementary Figure 3. Adipogenesis. Osteogenesis. Chondrogenesis.

250 views • 8 slides

Supplementary Figure 1

64 views • 2 slides

Supplementary Figure 1

Supplementary Figure 1. ***. 120000. 100000. ***. 80000. 60000. Relative light units (RLU). 40000. 20000. 0. Dox. +. -. +. -. Line I. Line 2. rtTA. rtTA. A. MMTV- rtTA TET0-PELP1 Line 1. MMTV- rtTA TET0-PELP1 Line 2. B. TetO-PELP1. MMTV- rtTA. WT. + Dox. T7-PELP1.

99 views • 1 slides

Supplementary Figure 1

A. *. A average weight [g]. A average weight [g]. CR. CR. Control. Control. T ime of experiment [week s ]. T ime of experiment [week s ]. *p<0,05. B. Supplementary Figure 1.

65 views • 1 slides

Supplementary Figure 1.

75 views • 1 slides

More Related